RetinAI, a provider of software solutions for image processing and artificial intelligence (AI) in ophthalmology, has introduced the RetinAI Discovery for Clinics platform.

The platform is launched in ophthalmology and optometry versions.

It is a vendor-neutral and multi-modality platform and aims to streamline clinical decision workflows, management of teleophthalmology, referral decisions and patient management, generating data efficiencies and improving decisions for clinics.  

The platform harmonises, aggregates and connects large datasets in a single, cloud-based repository.

Data is automatically analysed using RetinAI’s CE-marked and Research Use Only (RUO) AI algorithms, facilitating accelerated treatment decisions based on AI-derived biomarkers.

The AI models are compatible with DICOM and other formats for optical coherence tomography and fundus imaging.

Both versions of the Discovery for Clinics feature progression analytics, which assist in monitoring patient outcomes and provide detailed visualisations of disease progression to patients.

Discovery Passport, a key component of the platform, enables secure data sharing between healthcare providers and patients, along with remote questionnaires to bolster patient engagement and maintain quality care outside the clinic setting.

The platform supports referral networks and clinical trial participation through the collection of real-world data.

Additionally, the ophthalmology version of Discovery for Clinics includes RUO AI models for advanced analysis of Geographic Atrophy and a predictive model to forecast future atrophy progression.

RetinAI’s parent company Ikerian CEO and co-founder Dr Carlos Ciller said: “Discovery for Clinics is a powerful tool empowering not only physicians with enhanced AI-powered data insights to optimise outcomes and treatments but also patients, giving them access to their data.”